Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy of methylphenidate over placebo in
treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most
profound disturbances that occur in Alzheimer's dementia (AD).
Hypotheses: 1. Methylphenidate (MPH) will improve apathy significantly more than placebo in
AD.
2. Successful treatment of apathy will improve Instrumental Activities of Daily Living
(IADLs), and caregiver burden.